Clinical Oncology
Volume 18, Issue 6 , Pages 480-484 , August 2006

Diagnosis of Bone Metastasis in Men with Prostate Cancer by Measurement of Serum ICTP in Combination with Alkali Phosphatase and Prostate-specific Antigen

  • A. Kataoka

      Affiliations

    • Department of Urology, Shiga University of Medical Science, Otsu, Japan
    • ,
  • T. Yuasa

      Affiliations

    • Department of Urology, Shiga University of Medical Science, Otsu, Japan
    • Department of Urology, Akita University School of Medicine, Akita, Japan
    • Corresponding Author InformationAuthor for correspondence: Takeshi Yuasa, M.D., Department of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan. Tel: +81-18-884-6156; Fax: +81-18-836-2619.
    • ,
  • S. Kageyama

      Affiliations

    • Department of Urology, Shiga University of Medical Science, Otsu, Japan
    • ,
  • N. Tsuchiya

      Affiliations

    • Department of Urology, Akita University School of Medicine, Akita, Japan
    • ,
  • T. Habuchi

      Affiliations

    • Department of Urology, Akita University School of Medicine, Akita, Japan
    • ,
  • H. Iwaki

      Affiliations

    • Department of Urology, Shiga University of Medical Science, Otsu, Japan
    • ,
  • M. Narita

      Affiliations

    • Department of Urology, Shiga University of Medical Science, Otsu, Japan
    • ,
  • Y. Okada

      Affiliations

    • Department of Urology, Shiga University of Medical Science, Otsu, Japan
    • ,
  • T. Yoshiki

      Affiliations

    • Department of Urology, Shiga University of Medical Science, Otsu, Japan

Received 12 August 2005 ,Revised 29 December 2005 ,Accepted 13 February 2006.

References 

  1. Jemal A, Tiwari RC, Murray T, et al. American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29
  2. Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H. Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000;7:254–257
  3. Schroder FH. Hormonal therapy of prostate cancer. In:  Walsh PC,  Retik AB,  Vaughan ED,  Wein AJ editor. Campbell's urology. 8th edn. New York: Saunders; 2002;p. 3182–3208
  4. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713–2719
  5. Kylmala T, Tammela TL, Risteli L, Risteli J, Kontturi M, Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer. 1995;71:1061–1064
  6. Yoshida K, Sumi S, Arai K, et al. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Cancer. 1997;80:1760–1767
  7. Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai T, Ogata E. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol. 1997;157:539–543
  8. Noguchi M, Noda S. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol. 2001;166:1106–1110
  9. Noguchi M, Yahara J, Noda S. Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology. 2003;61:993–998
  10. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem. 1990;36:1328–1332
  11. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 1993;39:635–640
  12. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61:195–202
  13. Green JR. Antitumor effects of bisphosphonates. Cancer. 2003;97:840–847
  14. Saad F, Gleason DM, Murray R, et al. Zoledronic Acid Prostate Cancer Study Group: long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879–882
  15. Nogawa M, Yuasa T, Kimura S, et al. Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol Res. 2005;15:1–9
  16. Nogawa M, Yuasa T, Kimura S, et al. Monitoring luciferase-labeled cancer cell growth and metastasis in in vivo models. Cancer Lett. 2005;217:243–253
  17. Yuasa T, Nogawa M, Kimura S, et al. A third generation bisphosphonate, minodronic acid (YM529), augments the interferon α/β-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo. Clin Cancer Res. 2005;11:853–859
  18. Kylmala T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I. Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur J Cancer. 1993;29:821–825

PII: S0936-6555(06)00054-9

doi: 10.1016/j.clon.2006.02.010

Clinical Oncology
Volume 18, Issue 6 , Pages 480-484 , August 2006

Article Tools

* Image Usage & Resolution